Léi Gōng Téng (雷公藤) means "Thunder Duke Vine" — 雷 (Léi, thunder), 公 (Gōng, duke or lord), and 藤 (Téng, vine). It is named after Léi Gōng (雷公), the God of Thunder in Chinese mythology, reflecting the herb's powerful and dangerous nature. In the West it is commonly called Thunder God Vine. It is one of the most pharmacologically potent and simultaneously most toxic herbs in the Chinese materia medica — a plant that demands profound respect and caution, but which has attracted intense scientific attention for its remarkable anti-inflammatory, immunosuppressive, and anti-tumor properties.

Botanical name: Tripterygium wilfordii Hook. f. (Family: Celastraceae)

Part used: Root bark (inner bark of the root, with the highly toxic outer bark removed)

Nature: Cold

Flavor: Bitter, pungent

Meridians entered: Liver, Kidney

Toxicity: Highly toxic (大毒 Dà Dú). All parts of the plant are poisonous. The root bark is the least toxic part when properly processed.

Traditional Uses

Léi Gōng Téng first appeared in the Běncǎo Gāngmù Shíyí (本草纲目拾遗, Supplement to the Compendium of Materia Medica), compiled by Zhào Xuémín (赵学敏) in 1765 during the Qīng Dynasty. However, the plant was known long before as a potent insecticide — its extracts were documented in Wú Qíjùn's (吴其濬) 1848 Illustrated Catalogues of Plants as being used against agricultural pests.

Traditional actions include dispelling wind-dampness, activating blood circulation, clearing heat-toxin, reducing swelling, and killing parasites. It was used traditionally for conditions involving joint pain, swelling, skin lesions, and boils. Its use was always approached with extreme caution due to its well-known toxicity.

In the 1960s, Chinese researchers began systematically studying Léi Gōng Téng for the treatment of rheumatoid arthritis and other autoimmune conditions. Glycoside extracts of the root were developed into standardized preparations — Tripterygium wilfordii glycosides tablets — which were approved by China's State Food and Drug Administration for autoimmune and inflammatory diseases. These remain widely prescribed in China today.

Key Bioactive Compounds

More than 380 secondary metabolites have been isolated from Tripterygium wilfordii. The two most pharmacologically significant are triptolide and celastrol — both of which have generated substantial international research interest.

Triptolide (雷公藤甲素)

Triptolide is a diterpenoid triepoxide — a small molecule with extraordinary biological potency. It is the primary compound responsible for both the therapeutic effects and the toxicity of the plant. Research has identified its molecular target as XPB, a critical subunit of the TFIIH protein complex, which is involved in both DNA repair and the initiation of gene transcription. By binding covalently to XPB, triptolide functions as a global transcription inhibitor — it broadly reduces the production of new RNA from DNA templates. This mechanism underlies both its anti-inflammatory power (shutting down the production of inflammatory mediators) and its anti-tumor activity (inhibiting the transcriptional machinery that cancer cells depend on for rapid growth).

Celastrol (雷公藤红素)

Celastrol is a pentacyclic quinone triterpene with a distinct but complementary profile. It targets multiple signaling pathways including NF-κB (a master regulator of inflammation and immune response), heat shock proteins (which protect cancer cells from stress), and proteasome function. Where triptolide works primarily through transcription inhibition, celastrol operates through a broader network of protein interactions.

Anti-Tumor Research

The anti-cancer properties of Thunder God Vine compounds have been the subject of intensive research over the past four decades. The evidence comes primarily from laboratory studies (in vitro cell culture and in vivo animal models), with a small number of early-phase clinical trials now underway.

Mechanisms of Anti-Tumor Activity

Research has documented several mechanisms through which triptolide acts against cancer cells:

Transcription inhibition. By targeting TFIIH/XPB, triptolide broadly suppresses the transcriptional activity that rapidly dividing cancer cells require. Cancer cells, which depend heavily on ongoing gene expression for their survival and proliferation, are particularly vulnerable to this mechanism.

Apoptosis induction. Triptolide promotes programmed cell death in cancer cells through multiple pathways. It stabilizes the tumor suppressor protein p53 (preventing its degradation by MDM2), activates the p38 MAPK signaling pathway, and triggers mitochondrial-mediated apoptosis. These effects have been demonstrated across multiple cancer types in laboratory studies.

Anti-angiogenesis. Triptolide inhibits the formation of new blood vessels that tumors require for growth, starving the tumor of nutrients and oxygen.

Inhibition of metastasis. Laboratory studies have shown that triptolide can reduce the ability of cancer cells to migrate and invade surrounding tissues — the process by which cancer spreads from its original site.

Overcoming drug resistance. Research suggests that triptolide can enhance the sensitivity of drug-resistant cancer cells to conventional chemotherapy agents, potentially making it useful as a combination therapy.

Celastrol demonstrates complementary anti-tumor mechanisms, particularly through NF-κB pathway inhibition, proteasome disruption, and induction of cell cycle arrest.

Cancer Types Studied

Laboratory and preclinical studies have demonstrated anti-tumor effects of triptolide and celastrol against a range of cancer types, including pancreatic cancer, lung cancer, breast cancer (including triple-negative breast cancer), hepatocellular carcinoma (liver cancer), colorectal cancer, ovarian cancer, leukemia, and medulloblastoma. Pancreatic cancer has received particular attention because of the disease's poor prognosis with conventional treatments and the strong preclinical results shown by triptolide derivatives.

Minnelide: From Herb to Clinical Trial

The most significant step toward clinical application is Minnelide — a water-soluble prodrug of triptolide developed to overcome the compound's poor solubility and to improve its safety profile. Minnelide is converted to triptolide inside the body by phosphatases.

Minnelide showed potent anti-tumor activity in preclinical cancer models and has advanced to human clinical trials:

A Phase I clinical trial (ClinicalTrials.gov: NCT03129139), initiated in 2017, evaluated the safety, dosage, and bioavailability of Minnelide capsules — both alone and in combination with nab-paclitaxel — in patients with advanced solid tumors. Partial responses were noted in patients with gastric and pancreatic cancer.

A Phase II open-label trial (ClinicalTrials.gov: NCT03117920) has evaluated Minnelide specifically for advanced pancreatic cancer.

A separate Phase I trial (NCT03760523) began in 2019 to evaluate Minnelide in recurrent or refractory acute myeloid leukemia.

Another triptolide derivative, CK21, showed promising results in a 2023 study published in eLife, demonstrating significant tumor reduction in mouse models of pancreatic cancer with reduced toxicity compared to triptolide itself. The researchers found that CK21 worked by suppressing the NF-κB signaling pathway and triggering mitochondrial apoptosis.

Important Context

It is essential to understand what these findings represent — and what they do not:

What the research shows: Triptolide and celastrol have demonstrated genuine, reproducible anti-tumor effects in laboratory and animal studies. The mechanisms are well-characterized at the molecular level. Early-phase clinical trials of Minnelide have shown preliminary signs of activity in human cancer patients, particularly in pancreatic cancer.

What the research does not show: There is not yet conclusive evidence from large-scale, randomized clinical trials that Minnelide or other triptolide derivatives are safe and effective cancer treatments in humans. The compounds remain in early clinical development. The gap between promising preclinical results and proven clinical benefit is substantial — many compounds that work in laboratory settings fail in human trials.

The toxicity problem: Triptolide's therapeutic effects and its toxic effects arise from the same molecular mechanism — global transcription inhibition. This makes it inherently difficult to separate the desired anti-tumor activity from damage to healthy tissues. Hepatotoxicity (liver damage), nephrotoxicity (kidney damage), and cardiotoxicity (heart damage) are documented risks. The development of prodrugs like Minnelide and targeted delivery systems (nanoparticles, aptamer conjugates) represents ongoing efforts to solve this challenge.

Safety and Toxicity

Léi Gōng Téng is one of the most dangerous herbs in the Chinese materia medica. This cannot be overstated.

All parts of the plant are toxic. The outer bark of the root is the most dangerous; the inner root bark (used medicinally) is less toxic but still carries significant risk. Leaves, flowers, and skin of the root are not used medicinally.

Documented adverse effects of therapeutic extracts include gastrointestinal disturbance, liver damage, kidney damage, bone marrow suppression, amenorrhea (cessation of menstruation) in women, reduced sperm production in men, and skin reactions. Fatalities from ingestion of improperly prepared or excessive doses have been reported.

Drug interactions are significant. The immunosuppressive effects can compound with other immunosuppressive medications. Hepatotoxic potential increases when combined with other liver-taxing substances.

Processing is critical. Traditional preparation involves removing the outer bark and carefully extracting only specific fractions of the root. Modern pharmaceutical preparations use ethyl acetate or chloroform-methanol extraction to isolate the less toxic therapeutic fractions. Even with these precautions, adverse effects remain a significant concern.

This herb should never be self-administered. It requires prescription and monitoring by a qualified practitioner with specific expertise in its use. It is not a daily tonic, not a health supplement, and not comparable to gentle herbs like goji berry or ginseng.

Position in the Materia Medica

Léi Gōng Téng occupies a unique position in the Chinese herbal tradition. It is classified in the Lower Grade of medicinals — substances with powerful action and significant toxicity, reserved for serious conditions and short-term use under expert supervision. Its story illustrates a principle at the heart of Chinese herbal medicine: the same substance that heals can also harm. Dosage, preparation, combination, and clinical judgment determine the outcome.

The ongoing scientific investigation of Thunder God Vine's compounds represents one of the most active areas of research bridging traditional Chinese medicine and modern pharmacology. Whether triptolide derivatives will ultimately yield approved cancer therapies remains to be determined by rigorous clinical trials — but the molecular foundation is genuinely promising.